Vivani

vivani medical is a pre-clinical-stage developer of long-term pharmaceutical implants aimed at revolutionizing the treatment of patients with chronic diseases. leveraging its proprietary nanoportal™ platform, vivani’s portfolio of tiny, sub-dermal drug implants address medication non-adherence by providing steady levels of medication over a target duration of six months or longer. vivani is developing two miniature, long-term glp-1 implants for the treatment of obesity and chronic weight management: npm-115 (exenatide) and npm-139 (semaglutide). in addition, the company is developing npm-119, a lower dose exenatide implant for the treatment of type 2 diabetes.